title: Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
abstract: The purpose of this study was to clarify the efficacy and safety of docetaxel and cisplatin as second-line treatment for patients with S-1 refractory advanced gastric cancer. Between 1999 and 2006, 32 patients received docetaxel (60 mg/m²) and cisplatin (60 mg/m²) (Dp regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable toxicity was detected. The overall response rate was 21.9%. Seven patients showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were leukopenia and neutropnea. Non-hematological toxicities were generally mild to moderate and controllable. this study showed satisfactory therapeutic outcomes for patients with gastric cancer refractory to S- 1 chemotherapy.
authors.affiliation: Yokohama City University Medical Center, Gastroenterological, 4-57 Urafunecho, Minami-ku, Yokohama 232-0024, Japan. rtakagawa@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Takagawa
authors.forename: C
authors.initials: C
authors.lastname: Kunisaki
authors.forename: H
authors.initials: H
authors.lastname: Makino
authors.forename: Y
authors.initials: Y
authors.lastname: Nagano
authors.forename: S
authors.initials: S
authors.lastname: Fujii
authors.forename: J
authors.initials: J
authors.lastname: Kimura
authors.forename: T
authors.initials: T
authors.lastname: Kosaka
authors.forename: H A
authors.initials: HA
authors.lastname: Ono
authors.forename: H
authors.initials: H
authors.lastname: Akiyama
authors.forename: I
authors.initials: I
authors.lastname: Endo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D000077143:Docetaxel; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000494:pharmacology; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy*; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000494:pharmacology; D057832:Watchful Waiting
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D002945:Cisplatin